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Abstract
Background: Vitamin D insufficiency has been associated with the occurrence of various types of cancer, but causal
relationships remain elusive. We therefore aimed to determine the relationship between genetic determinants of vitamin D
serum levels and the risk of developing hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC).
Methodology/Principal Findings: Associations between CYP2R1, GC, and DHCR7 genotypes that are determinants of reduced
25-hydroxyvitamin D (25[OH]D3) serum levels and the risk of HCV-related HCC development were investigated for 1279
chronic hepatitis C patients with HCC and 4325 without HCC, respectively. The well-known associations between CYP2R1
(rs1993116, rs10741657), GC (rs2282679), and DHCR7 (rs7944926, rs12785878) genotypes and 25(OH)D3 serum levels were also
apparent in patients with chronic hepatitis C. The same genotypes of these single nucleotide polymorphisms (SNPs) that are
associated with reduced 25(OH)D3 serum levels were found to be associated with HCV-related HCC (P= 0.07 [OR= 1.13, 95%
CI = 0.99–1.28] for CYP2R1, P=0.007 [OR= 1.56, 95% CI = 1.12–2.15] for GC, P=0.003 [OR= 1.42, 95% CI = 1.13–1.78] for DHCR7;
ORs for risk genotypes). In contrast, no association between these genetic variations and liver fibrosis progression rate (P.0.2
for each SNP) or outcome of standard therapy with pegylated interferon-a and ribavirin (P.0.2 for each SNP) was observed,
suggesting a specific influence of the genetic determinants of 25(OH)D3 serum levels on hepatocarcinogenesis.
Conclusions/Significance: Our data suggest a relatively weak but functionally relevant role for vitamin D in the prevention
of HCV-related hepatocarcinogenesis.
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Introduction
Chronic hepatitis C is associated with important morbidity,
resulting in liver cirrhosis and its complications in a significant
proportion of infected individuals [1]. Due to the rising age of the
hepatitis C virus (HCV)-infected population in the Western world,
a dramatic increase of cases with advanced liver cirrhosis and
hepatocellular carcinoma (HCC) has been predicted for the next
decade [1]. Due to the insufficient treatment options for advanced
HCC as well as limited number of liver allograft donors for
patients with curable disease, improved strategies to screen for
early HCC or to prevent the development of HCC are warranted
[2]. Recently, two genome-wide association studies (GWAS) have
identified single nucleotide polymorphisms (SNPs) in the region of
DEPDC5 and MICA as susceptibility loci for HCC development in
patients with chronic hepatitis C [3,4]. Although these genetic
variations were strongly associated with HCV-induced HCC, with
potentially important implications for the identification of patients
at high risk of developing HCC, it might be challenging to
translate these findings into novel therapeutic strategies for HCC.
Vitamin D insufficiency is common in different populations
worldwide and has been associated with the presence of various
types of cancer, including HCC [5–7]. These observations
attracted considerable interest because vitamin D can be easily
supplemented, with only infrequent side-effects and little costs.
Yet, it has remained mostly unclear whether there is a causal
association between vitamin D insufficiency and cancer develop-
ment, or whether reduced vitamin D serum levels are simply
surrogates for other circumstances in cancer patients (e.g.
malnutrition, limited exposure to sunlight) [5–7]. Recently, two
large GWAS have identified SNPs at three loci (GC, encoding the
vitamin D binding protein; DHCR7, encoding 7-dehydrocholes-
terol reductase; and CYP2R1, encoding a liver 25-hydroxylase) as
genetic determinants of reduced 25(OH)D3 serum levels [8,9]. We
hypothesized, that associations between these genetic variations
and the occurrence of malignant or other diseases may provide a
stronger argument for a causal relationship between vitamin D
and the development of such diseases than the investigation of
(punctual) vitamin D serum levels. In view of the high prevalence
of severe vitamin D deficiency in patients with chronic hepatitis C
[10], we therefore sought to investigate the association between
genetic variations in CYP2R1, GC, and DHCR7 and HCV-induced
HCC.
Methods
Objectives
Genetic variations in three independent genes, CYP2R1, GC,
and DHCR7, are associated with life-long reduced 25(OH)D3
serum levels [9]. Vitamin D insufficiency has been associated with
the occurrence of various types of cancer, but causal relationships
remain elusive. Therefore, we hypothesized that genetic determi-
nants of 25(OH)D3 serum levels may be associated with HCV-
related HCC if there is a causal relationship between vitamin D
metabolism and HCC development in chronic hepatitis C
patients. Hence, we assessed associations between the presence
of HCC in HCV infected patients and genetic variants in CYP2R1,
GC, and DHCR7 in the primary analysis of the present study.
Participants
For the primary analysis of the present study, the association
between HCV-induced HCC and genetic variants in CYP2R1, GC,
and DHCR7, four independent cohorts of HCV-infected individuals
were investigated, two cohorts including Caucasians and two
cohorts including Japanese individuals. All cohorts include consec-
utive patients from various outpatient clinics; hence the prevalence
of HCC in our cohorts is not representative of the prevalence of
HCC in HCV-infected patients in general.
The first Caucasian cohort was selected from patients enrolled
in the Swiss Hepatitis C Cohort Study (SCCS). The SCCS is a
multicenter study pursued at 8 major Swiss hospitals and their
local affiliated centers, including a total of 3,648 patients with
chronic or resolved HCV infection [11]. For the present analysis,
SCCS patients were included in our study if they had chronic
hepatitis C, had provided written informed consent for genetic
testing, had genomic DNA available for testing, if they were
Caucasian, and if the duration of infection with HCV was known.
Patients with hepatitis B virus infection were excluded from the
discovery cohort, as well as from the replication cohorts. A second,
independent cohort of Caucasian patients with chronic HCV
infection with or without HCC was identified (designated as
Berlin/Bonn cohort in the following); these patients were recruited
at the University Hospital Departments of Gastroenterology and
Hepatology in Bonn, Berlin and Leipzig in Germany, as described
in Nischalke et al [12]. In addition, two independent cohorts of
Japanese patients with chronic hepatitis C with or without HCC
were included (a detailed description of these cohorts is provided
in Miki et al. [4]; the cohorts are designated as Japanese GWAS
and Japanese Replication cohort, as in Miki et al.). Importantly,
the duration of infection with HCV was known in patients of the
SCCS but not in the three additional cohorts.
In addition to the primary analysis of this study, a number of
sub-analyses were performed in order to validate our research
strategy. These sub-analyses investigated possible associations
between genetic variations in CYP2R1, GC and DHCR7 and i)
liver fibrosis progression rate (FPR), ii) response to treatment with
pegylated interferon-a (PEG-IFN-a) and ribavirin, and iii)
25(OH)D3 serum levels. These sub-analyses were performed in
SCCS patients only because of the thorough documentation of
these end-points together with the known duration of infection in
the SCCS. FPR was defined as a dichotomized phenotype (, vs.$
sex-adjusted median FPR), which was calculated on the basis of
the ratio of the METAVIR fibrosis score to the estimated duration
of infection in years until liver biopsy (METAVIR units per year),
as described previously [13]. Hence, all SCCS patients with at
least one available liver biopsy with fibrosis staging prior to
antiviral treatment and with known date of infection were included
in the analyses of FPR. The treatment response analyses was
restricted to SCCS patients who were treated under clinical
practice conditions with either PEG-IFN-a2a or PEG-IFN-a2b in
combination with weight-based ribavirin, with standard treatment
durations (48 weeks for HCV genotype 1 and 4, 24 weeks for
HCV genotype 2 and 3), and if they had received $80% of the
recommended dose of both agents during the first 12 weeks of
therapy. SVR was defined as HCV RNA below the limit of
detection in a sensitive assay $24 weeks after treatment
completion, and all patients who failed to achieve SVR were
classified as nonresponders. Serum concentrations of 25(OH)D3
were determined in all SCCS patients with chronic hepatitis C in
whom a plasma sample at baseline of antiviral therapy or at the
time of a liver biopsy was available. Demographic and clinical
characteristics were extracted from clinical databases. High
alcohol intake was defined as consumption .40 g per day over
a period of$5 years. Liver biopsies were evaluated by experienced
local pathologists. Liver fibrosis was classified according to the
METAVIR score. Necroinflammatory activity was stratified into
two groups, absent to mild activity vs. moderate to high activity.
Steatosis was classified as absent or present. HCC was diagnosed
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either by biopsy or, in selected cases, by typical presentation in two
independent imaging modalities. The study was approved by local
ethical committees.
Description of Investigations Undertaken
In a recent GWAS, Wang et al. have identified three loci
(CYP2R1, GC, and DHCR7) to be associated with reduced
25(OH)D3 serum levels [9]. Importantly, a second independent
GWAS by Ahn et al. yielded similar results and confirmed the
association between the three loci and 25(OH)D3 serum levels [8].
From these studies, we selected the most significant SNPs for each
locus (rs1993116 and rs10741657 in CYP2R1; rs2282679 in GC;
rs7944926 and rs12785878 in DHCR7). rs10741657 and
rs1993116 in CYP2R1 as well as rs7944926 and rs12785878 in
DHCR7 are in high LD (Table S1). Hence, these SNPs can be
substituted by each other for an investigation of the association
between the indicated loci and HCV-related HCC, and either
rs7944926 or rs12785878 in DHCR7 and either rs10741657 or
rs1993116 in CYP2R1 were genotyped in each of the four cohorts.
Specific SNPs were selected according to availability in our
databases, as genotyping of these SNPs was either performed in
the context of previous GWA studies of our cohorts [4,14], or by
using a fluorescent-based competitive allele-specific PCR geno-
typing system (KBioscience, UK) using the primers listed in Table
S2. SNPs in CYP27B1, which we have previously shown to be
associated with SVR [10,15], were not included in the present
study as they are believed to be predominantly important during
the rapid regulation of calcitriol tissue levels in inflammatory
responses, and because they have no impact on 25(OH)D3 serum
levels.
Measurement of 25(OH)D3 was performed as described
previously [10].
Ethics
The study was approved by local ethical committees of each
affiliation (Switzerland: Universita¨tsspital Basel, Basel; Inselspital,
Bern; University Hospital Geneva, Geneva; CHUV, Lausanne;
Ospedale Moncucco, Lugano; Hoˆpital Neuchaˆtelois, Neuchatel;
Kantonsspital St. Gallen, St. Gallen; Universita¨tsspital Zu¨rich,
Zu¨rich; Germany: University of Berlin, Berlin; University of Bonn,
Bonn; Japan: University of Hiroshima, Hiroshima), and written
informed consent was received from all participants.
Statistical Analyses
Testing for Hardy-Weinberg equilibrium and linkage disequi-
librium (LD) was performed with the genhw and pwld packages in
Stata (version 9.1, StataCorp, College Station, TX). Associations
of SNPs with risk of HCV-induced HCC (dichotomic variable
HCC vs. no HCC) were assessed with x2 contingency tables, and –
in the SCCS in patients with known duration of infection – in uni-
and multivariate Cox regression models. Associations between
SNPs and treatment outcome (SVR vs. no SVR) and with FPR
(below vs. above sex-adjusted median FPR) were assessed in
logistic regression models and Cox regression models, respectively.
In regression models, SNPs were analyzed using an additive model
(none, one or two copies of the minor allele were coded 0, 1 and 2,
respectively, assuming greater effect with increased copy number
of the minor allele), unless otherwise specified.
Results
Patient Characteristics
Out of a total of 3,648 patients enrolled in the SCCS, 1661
patients with known duration of infection were included in the
primary analyses of the present study based on the selection
criteria defined above. Out of these patients, 50 individuals
developed HCC. The three additional cohorts included a total
number of 1229 patients with chronic hepatitis C and HCC, as
well as 2714 patients with chronic hepatitis C without HCC at the
time of the analysis. Thus, the primary analysis of the present
study included 1279 chronic hepatitis C patients with HCC and
4325 without HCC. Baseline characteristics of these patients are
summarized in Table 1.
In addition, 963 and 750 SCCS patients were eligible to assess
the impact of genetic variations in CYP2R1, GC, and DHCR7 on
FPR and on the outcome of standard treatment with PEG-IFN-a
and ribavirin, respectively. Serum levels of 25(OH)D3 were only
available in a minority for 496 SCCS patients.
Table 1. Baseline characteristics of included patients.
SCCS Japanese GWAS Japanese Repl. Bonn/Berlin
HCC Control HCC Control HCC Control HCC Control
N 50 1611 310 1252 803 1253 116 209
Age (SD)1 28* (15) 21 (10) – – – – 61*
(10.6)
48
(12.4)
Male sex, n (%)1 31 (62) 991(62) 230 (74)* 725 (58) 515 (64)* 570 (45) 73 (58) 114 (55)
Alcohol ($40 g/d $5 years), n (%)2 3 (8) 220 (17) – – – – – –
Diabetes, n (%) 9 (18)* 91 (6) – – 254 (32)* 219 (18) – –
HCV Genotype, n (%)3
1, 4 27 (60) 1014 (64) 307 (99) 1241 (99) 540 (72)* 837 (67) – –
2, 3 17 (40) 570 (36) 2 (1) 10 (1) 213 (28)* 416 (33) – –
*These comparisons between HCC cases and controls are statistically significant (P,0.05). Repl, replication. The cohort labeling ‘‘Japanese GWAS’’ and ‘‘Japanese
Replication’’ is based on the initial description of the cohorts in Miki et al., for the present study both cohorts served as replication cohorts.
1Age and sex data was missing in 5 patients in the Bonn/Berlin cohort. For the SCCS, age of infection is shown. Age of infection was unknown for the Bonn/Berlin
cohort, for this cohort age at diagnosis is shown.
2Alcohol consumption data was missing in 12 HCC and 290 non-HCC patients from the SCCS.
3HCV genotype was missing in 5 HCC and 23 non-HCC patients from the SCCS, in 1 HCC and 2 non-HCC patients from the Japanese GWAS, and 50 HCC patients from
the Japanese replication cohorts.
doi:10.1371/journal.pone.0064053.t001
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Association between Genetic Determinants of 25(OH)D3
Serum Levels and HCV-induced HCC
Median 25(OH)D3 serum levels in patients with chronic
hepatitis C with or without HCC in the SCCS were 12.7 and
14.3 ng/mL, (range 4.9–40.9 and 3.9–76.9) respectively (P=0.19,
values available in 496 patients). However, 25(OH)D3 serum levels
fluctuate strongly during seasons and as a consequence of
numerous circumstances such as exposure to sunlight, nutrition,
accompanying diseases, vitamin D supplementation and others.
We therefore believe that genetic variants in CYP2R1, GC, and
DHCR7, with their proven impact on 25(OH)D3 serum levels,
should be used as surrogates for long-term 25(OH)D3 serum levels.
Hence, we genotyped the most relevant tagging SNPs for these loci
(rs1993116/rs10741657 for CYP2R1, rs2282679 for GC,
rs7944926/rs12785878 for DHCR7; data on LD and Hardy
Weinberg equilibrium for these SNPs are shown in Table S1), and
assessed their association with HCV-related HCC.
Table 2 summarizes results of the primary analysis for
associations between HCV-related HCC and genetic variations
in CYP2R1, GC, and DHCR7 in the four independent patient
cohorts. In the combined analyses of these cohorts, the strongest
association with HCV-induced HCC was found for GC (P=0.007,
OR=1.56, 95% CI= 1.12–2.15) and DHCR7 (P=0.003,
OR=1.42, 95% CI= 1.13–1.78), whereas CYP2R1 was almost
significantly associated with HCV-induced HCC (P=0.07,
OR=1.13, 95% CI=0.99–1.28). Remarkably, in each indepen-
dent cohort, frequencies and ORs for the risk alleles at each locus
showed an association in the similar direction, even though
statistical significance was not reached for all subgroups.
Of note, genotyping of rs1287578 in DHCR7 revealed huge
differences of T allele frequencies between Caucasian and
Japanese cohorts. These differences are in line with allele
frequencies reported in HapMap. Since previous GWAS on
vitamin D serum levels did not include relevant numbers of Asian
Table 2. Summary of associations between SNPs in CYP2R1, GC, and DHCR7, and HCV-related hepatocellular carcinoma
development.
CYP2R1
Cases Controls
Risk allele
frequencies
SNP Study Allele 1/2 11 12 22 11 12 22 Case Control P OR (95% CI)
rs1993116 SCCS A/G 6 16 28 199 774 634 0.72 0.64 0.02 1.95 (1.18–3.41)
rs1993116 Japanese
GWAS
A/G 41 136 133 163 621 468 0.65 0.62 0.07 1.26 (0.98–1.61)
rs107416571 Japanese
Replication
A/G 106 377 320 174 597 482 0.63 0.62 0.5 1.06 (0.88–1.27)
rs1993116 Bonn-Berlin A/G 17 48 47 25 98 81 0.63 0.64 0.7 1.10 (0.67–1.76)
Combined A/G 170 577 528 561 2090 1665 0.64 0.63 0.07 1.13 (0.99–1.28)
GC
SNP Study Allele 1/2 11 12 22 11 12 22 Case Control P OR (95% CI)
rs2282679 SCCS T/G 26 20 4 855 641 104 0.28 0.27 0.6 1.25 (0.44–3.54)
rs2282679 Japanese
GWAS*
T/G 153 125 31 679 475 97 0.30 0.27 0.19 1.33 (0.87–2.03)
rs2282679 Bonn-Berlin T/G 55 46 15 117 77 14 0.33 0.25 0.06 2.01 (0.97–4.38)
Combined T/G 234 191 50 1651 1193 215 0.31 0.27 0.007 1.56 (1.12–2.15)
DHCR7
SNP Study Allele 1/2 11 12 22 11 12 22 Case Control P OR (95% CI)
rs7944926 SCCS T/C 17 10 4 462 310 55 0.29 0.25 0.9 1.04 (0.51–2.14)
rs7944926 Japanese
GWAS
T/C 127 156 27 599 534 119 0.34 0.31 0.03 1.32 (1.03–1.70)
rs127858782 Japanese
Replication
T/G 84 336 383 153 543 557 0.69 0.66 0.15 1.13 (0.95–1.36)
rs127858782 Bonn-Berlin T/G 63 44 9 113 77 18 0.27 0.27 1.00 1.00 (0.63–1.58)
Combined# T/C 144 166 31 1061 844 174 0.33 0.29 0.003 1.42 (1.13–1.78)
Allele 2 indicates the risk allele, according to Wang et al. [9]. P-values and ORs were calculated for risk genotypes using favorable genotypes as a reference, i.e. for
CYP2R1 by comparing GG vs. GA/AA genotypes, for GC by comparing TT/TG vs. GG genotypes, and for DHCR7 by comparing TT vs. TC/CC genotypes.
#Only patients from the SCCS and Japanese GWAS were included in the combined analysis for this locus, because of the different allele frequencies for rs12785878 in
Japanese patients compared to Caucasian patients. Data remain significant after inclusion of the Bonn-Berlin cohort (P = 0.018, OR = 1.27 [95% CI = 1.04–1.56]).
*Genotyping of this SNP failed in the Japanese Replication cohort due to limited amounts of DNA. Please note that the total number of patients with available
genotypes is not equal between different loci due to limited amount of DNA or genotyping failure in some cases.
1rs1993116 and rs10741657 are in complete LD in the Caucasian and Japanese population (R2 = 0.95 and = 1.00, respectively), the major alleles of both SNPs have a
similar impact on 25(OH)D3 serum levels, indicating that both SNPs can be used equivalently [9].
2rs7944926 and rs12785878 are in complete LD in the Caucasian and Japanese population (R2 = 1.00 and = 1.00, respectively), the major alleles of both SNPs have a
similar impact on 25(OH)D3 serum levels, indicating that both SNPs can be used equivalently [9].
doi:10.1371/journal.pone.0064053.t002
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individuals, a functional interpretation of rs1287578 genotyping
data in Japanese appears to be difficult, as the risk allele for this
SNP in Asians has not yet been clearly identified. Therefore, data
for rs1287578 genotype in the Japanese replication cohort were
not included in the combined analysis shown in Table 2.
The known duration of infection allowed an additional cox
regression analyses of the risk of HCC in patients from the SCCS.
Figure 1 shows the cumulative incidence of HCC in patients with
the CYP2R1 risk genotype rs1993116 GG compared to those with
the favorable genotypes GA and AA (P=0.037, hazard ratio
(HR) = 1.81 (95% confidence interval (CI) = 1.03–3.13).
To exclude a possible selection bias within the SCCS, a
subanalysis was performed in which the inclusion criterion
‘‘known duration of infection’’, which was specific for the SCCS,
was omitted. As shown in Table S3, results of this case-control
study are largely comparable to the primary analysis of our study.
Association between Genetic Determinants of 25(OH)D3
Serum Levels and Liver Fibrosis Progression Rate (FPR)
and Treatment Outcome
Thus far, we cannot completely exclude that the above
described associations between genetic determinants of reduced
25(OH)D3 serum levels and HCV-induced HCC are primarily
mediated by an effect of the indicated SNPs on FPR or treatment
outcome. We therefore performed sub-analyses to test whether
FPR or treatment outcome are associated with variations in
CYP2R1, GC and DCHR7. In 963 SCCS patients in whom FPR
could be calculated, none of the SNPs was significantly associated
with slow vs. fast FPR (P=0.2 for rs1993116 in CYP2R1; P=0.5
for rs2282679 in GC, and P=0.3 for rs7944926 in DHCR7;
Table 3). In addition, in 750 SCCS patients who had received
standard therapy with PEG-IFN-a and ribavirin, no significant
associations were found between SNPs in CYP2R1, GC and
DHCR7 and treatment outcome (SVR vs. no SVR; P=0.9, 0.4,
0.2, respectively; Table 4), suggesting that the observed associa-
tions between these loci and HCC are specific for (HCV-induced)
hepatocarcinogenesis. Finally, we calculated 25(OH)D3 serum
levels according to CYP2R1, GC, and DHCR7 genotypes.
25(OH)D3 serum levels were 14.9, 13.4 and 12.4 ng/mL in
patients with CYP2R1 rs1993116 genotype AA, AG, and GG
(P=0.41), respectively; 14.4, 14.2, 11.7 in patients with GC
rs2282679 genotype TT, TG, GG (P=0.037); and 14.3, 14.4, and
13.1 in patients with DHCR7 rs7944926 genotype TT, TC, and
CC (P=0.44).
Discussion
The present study shows that genetic variations in CYP2R1, GC,
and DHCR7 are associated with progression to HCC in patients
with chronic hepatitis C. The SNPs investigated in CYP2R1, GC,
and DHCR7 have been identified by two independent GWAS as
relevant genetic determinants of reduced 25(OH)D3 serum levels
[8,9]. Although genetic association studies cannot prove causal
relationships between genetic variations and specific phenotypes,
the association here identified between three genetically indepen-
dent, but functionally related susceptibility loci of vitamin D
deficiency and HCV-induced HCC suggest that an impaired
vitamin D metabolism (functionally) contributes to hepatocarcin-
ogenesis in HCV-infected patients. Importantly, the lack of
association of these SNPs in CYP2R1, GC, and DHCR7 with
FPR and response to treatment with PEG-IFN-a and ribavirin
suggests a specific effect of these genetic variations on HCV-
induced hepatocarcinogenesis.
Figure 1. Risk of hepatocellular carcinoma (HCC) development in SCCS patients with chronic hepatitis C and known duration of
infection, according to CYP2R1 rs1993116 genotypes. The probability to develop HCC from the time of hepatitis C virus infection by CYP2R1
rs1993116 genotypes (GG vs. GA/AA) was assessed by using cumulative incidence curves, with censoring of data at the date of last follow-up or
death. Statistics are shown for univariate Cox regression analysis. CI, confidence interval; HR, hazard ratio.
doi:10.1371/journal.pone.0064053.g001
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Vitamin D insufficiency has been previously linked to the
development of HCC [16]. However, causal relationships
remained mostly unclear because these studies were small or
concentrated on the assessment of 25(OH)D3 serum levels at the
date of HCC, which may result in false-positive associations due
the influence of impaired liver function on circulating 25(OH)D3
[5,16–18]. In addition, randomized controlled clinical trials
evaluating the effect of vitamin D or its analogues on HCC
development are lacking. Thus, the results of the present, large-
scale genetic association study add a significant argument to
evaluate the possible chemo-preventive effect of vitamin D
supplementation in HCV-infected patients. However, although
our data suggest a causal role of vitamin D metabolism in HCV-
induced HCC, there is currently no published evidence that
vitamin D supplementation would translate into a benefit in HCV-
infected patients with advanced liver disease. In this regard,
caution is advisable since some placebo-controlled studies evalu-
ating the supplementation of other vitamins have reported a
reduced overall survival rate in some verum groups [19]. Yet, in
view of our present data, and in view of the high prevalence of
severe vitamin D deficiency in patients with chronic hepatitis C
[10,20,21], randomized controlled clinical trials in HCV-infected
patients with advanced liver disease appear to be justified.
Limitations
Our study has potential limitations. First, 25(OH)D3 serum
levels were only available in a relatively small subgroup of patients.
Nevertheless, we observe the same trends for 25(OH)D3 serum
levels according to CYP2R1, GC, and DHCR7 genotypes as
described previously, and HCV-infected patients with HCC had
slightly lower 25(OH)D3 serum levels compared to those without
HCC. More important, we believe that analyses of associations
between punctual 25(OH)D3 serum levels and endpoints such as
HCC can be misleading, since 25(OH)D3 serum levels strongly
fluctuate during seasons, with age, and as a consequence of
numerous other conditions (liver fibrosis, diabetes, obesity,
supplementation, etc.) [6,7]. A second limitation of our study is
the relatively weak level of statistical significance in the analyses of
the individual cohorts, with the consequence that associations for
the three loci with HCC became only fully significant in the
combined analyses of all included patients. Most likely, this can be
explained by the relatively low frequency of the risk genotypes
(especially of GC and DHCR7), as well as by the numerous
variables with influence 25(OH)D3 serum levels in a given
individual [9]. In this regard, it is important to note that ORs
for the risk genotype of all genes (CYP2R1, GC, and DHCR7) were
similarly directed in the discovery cohort as well as in all
replication cohorts, confirming a true association between these
loci and HCV-induced HCC. In addition, the strengths of the
associations between these loci and HCV-induced HCC were
largely comparable to the strength of the associations between
these loci and 25(OH)D3 serum levels (strong effect of GC and
DHCR7, moderate effect of CYP2R1, according to Wang et al.) [9].
Nevertheless, the observed subtle differences between the different
cohorts included in our study may not only be explained by the
relatively small sample size of individual cohorts, but also by
specific cohort features such as different recruitment strategies (e.g.
cohort study versus case-control studies). In this regard, our study
also cannot fully rule out whether all investigated genes (CYP2R1,
GC, DHCR7) have the same impact on progression to HCV-
related HCC at different stages of liver disease or in populations of
different ancestries. Furthermore, our study cannot clearly
characterize whether the observed findings apply for patients
who did or did not respond to antiviral therapy. Though we show
in the SCCS (in a minority of the whole study population), that
SNPs in CYP2R1, GC, and DHCR7 were not associated with
treatment outcome, it remains unclear whether these genetic
variations are associated with HCC in both individuals with or
without treatment-induced eradication of HCV.
The heterogeneity of the four independent cohorts included in
our analyses might be perceived as another limitation. This applies
for important cohort features such as race, recording of treatment
modalities, HCC frequency, or different allele frequencies for
some SNPs (especially rs1278578).
Conclusions
In conclusion, we provide evidence for a functionally relevant
contribution of reduced 25(OH)D3 serum levels to HCV-induced
Table 3. Association of SNPs in CYP2R1, GC, and DHCR7 with
liver fibrosis progression rate (FPR) in patients with chronic
hepatitis C.
Patients, n (%)
Gene SNP Gt Slow FPR* Fast FPR* P OR (95% CI)
CYP2R1 rs1993116 GG 183 (41) 192 (37)
GA 213 (48) 263 (51) 0.2 1.20 (0.93–1.56)
AA 47 (11) 65 (13)
GC rs2282679 TT 236 (53) 266 (51)
TG 175 (40) 217 (42) 0.5 1.08 (0.84–1.39)
GG 31 (7) 34 (7)
DHCR7 rs7944926 TT 160 (54) 221 (58)
TC 115 (39) 139 (36) 0.3 0.85 (0.63–1.16)
CC 22 (7) 22 (6)
*FPR, liver fibrosis progression rate. Slow vs. fast FPR was defined as FPR,vs. $
sex-adjusted median FPR in METAVIR-units per year. Statistics are shown for
logistic regression analyses based on the additive model of inheritance. The
usage of other models of inheritance (recessive, dominant) did not result in
significant associations as well (not shown).
doi:10.1371/journal.pone.0064053.t003
Table 4. Association of SNPs in CYP2R1, GC, and DHCR7 with
response to treatment of pegylated interferon-a and ribavirin
in patients with chronic hepatitis C.
Patients, n (%)
Gene SNP Gt without SVR with SVR P OR (95% CI)
CYP2R1 rs1993116 GG 109 (38) 171 (37)
GA 138 (48) 238 (52) 0.9 1.03 (0.76–1.39)
AA 42 (15) 52 (11)
GC rs2282679 TT 166 (57) 248 (54)
TG 105 (36) 186 (40) 0.42 1.14 (0.85–1.54)
GG 19 (7) 26 (6)
DHCR7 rs7944926 TT 127 (53) 230 (58)
TC 95 (40) 143 (36) 0.2 0.81 (0.59–1.12)
CC 17 (7) 22 (6)
Statistics are shown for logistic regression analyses based on the additive model
of inheritance. The usage of other models of inheritance (recessive, dominant)
did not result in significant associations as well (not shown).
doi:10.1371/journal.pone.0064053.t004
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HCC. Controlled clinical trials to evaluate the impact of vitamin D
supplementation on HCC risk and overall survival in patients with
chronic hepatitis C appear to be justified.
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